T1	OtherOutcome 375 385	heart rate
T2	OtherOutcome 387 403	body temperature
T3	OtherOutcome 405 419	blood pressure
T4	OtherOutcome 421 444	oxygen saturation (SO2)
T5	OtherOutcome 451 458	dyspnea
T6	OtherOutcome 460 465	cough
T7	OtherOutcome 467 509	gastrointestinal involvement (GI) symptoms
T8	OtherOutcome 511 518	myalgia
T9	OtherOutcome 520 530	chest pain
T10	OtherOutcome 536 546	BORG score
T11	OtherOutcome 637 758	need on oxygen therapy (nasal cannula, mask oxygen, reserve mask, noninvasive ventilation (NIV), and invasive ventilation
T12	OtherOutcome 845 861	CT scan findings
T13	OtherOutcome 1001 1015	mortality rate
T14	OtherOutcome 1021 1069	duration of hospitalization in improved patients
T15	OtherOutcome 1079 1135	time (in days) from the initiation of treatment to death
T16	OtherOutcome 1165 1188	Laboratory test results
T17	OutcomeDefinition 1208 1502	blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), vein blood gas analysis (VBG) including PH, Bicarbonate (HCO3), and partial pressure of carbon dioxide (PCO2), IL-6, Ferritin, Troponin, D-dimer, lactic acid dehydrogenase (LDH), and creatine phosphokinase (CPK)
R1	DefinedAs Arg1:T16 Arg2:T17	
T18	OtherOutcome 1589 1628	Clinical signs of the improved patients
T19	OutcomeDefinition 1630 1695	including cough, GI symptoms, myalgia, chest pain, and BORG score
R2	DefinedAs Arg1:T18 Arg2:T19	
T20	PrimaryOutcome 1897 1987	time of clinical improvement and discharge from the hospital or death whichever came first
T21	OutcomeDefinition 1989 2287	Hospital discharge was determined according to the patients clinical and laboratory findings. Improvement was defined as BORG score>3, improved dyspnea, stopped fever for 72 hours, SO2> 93%, tolerated oral regimen (PO), normal urinary output and reduced CRP level without any treatment side effects
R3	DefinedAs Arg1:T20 Arg2:T21	
